HOME >> MEDICINE >> NEWS
Asthmatx completes enrollment in pivotal study of bronchial thermoplasty

San Francisco, CA, May 21, 2007 Asthmatx, Inc., a medical device company that has developed a catheter-based procedure for the treatment of asthma, announced today the successful completion of enrollment in its pivotal FDA approved IDE study, the Asthma Intervention Research 2 (AIR2) Trial of the Alair Bronchial Thermoplasty System. Bronchial Thermoplasty is a non-drug treatment for asthma under clinical investigation in the United States. The minimally invasive, bronchoscopic procedure uses thermal energy to reduce the airway smooth muscle responsible for constriction in asthma patients.

Leading asthma and bronchoscopy experts are participating in this international, multicenter AIR2 Trial to establish the safety and efficacy of the Alair System. Nearly 300 patients were enrolled in the study during the last 18 months at over 30 world-renowned medical centers including 15 US research hospitals. The AIR2 Trial is the fourth clinical study of the Alair Bronchial Thermoplasty System. To date, over 700 bronchoscopic procedures have been performed on asthma patients.

"We are very pleased to be a participant in this very important AIR2 Trial, the success of which will result in an important advancement in the treatment of severe asthma," states Mario Castro, MD, Associate Professor at the Washington University School of Medicine and Asthma Center, and a Principal Investigator in the AIR2 Trial. "As the lead enrolling center in the United States, we have experienced significant patient interest in bronchial thermoplasty, which we hope may become a new option for patients with difficult-to-treat asthma."

Final results of the first randomized and controlled clinical study of bronchial thermoplasty, the Asthma Intervention Research (AIR) Trial, were also reported today at the annual scientific assembly of the American Thoracic Society (ATS) by Gerard Cox, MB, Professor of Medicine, McMaster University, Canada, and principal investigato
'"/>

Contact: Meghan Oreste
moreste@comcast.net
617-823-1441
Asthmatx
21-May-2007


Page: 1 2

Related medicine news :

1. Acrux completes enrollment in key phase 2 trial
2. MacroChem completes patient enrollment for Phase II trial of EcoNail for treatment of onychomycosis
3. GroPep completes final milestone of the path malaria vaccine initiative
4. Im a Kid Too project completes first phase
5. Approval to start US BTT pivotal trial
6. Bayer and Onyx announce pivotal Nexavar kidney cancer study published in NEJM
7. New data show CAS in clinical practice has comparable MAE rate with pivotal sapphire trial
8. Now is a pivotal point in history to abolish state execution
9. Orqis Medical receives unconditional FDA approval for pivotal trial of percutaneous CHF therapy
10. Childhood obesity indicates greater risk of school absenteeism, Penn study reveals
11. Penn study finds pro-death proteins required to regulate healthy immune function

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/26/2016)... ... ... Brent Kasmer, a legally blind and certified personal trainer is helping to develop a weight ... app plans to fix the two major problems leading the fitness industry today:, ... program , They don’t eliminate all the reasons people quit their exercise program ...
(Date:6/25/2016)... ... June 25, 2016 , ... Experts from the American Institutes ... Research Meeting June 26-28, 2016, at the Hynes Convention Center in Boston. , ... advance care planning, healthcare costs and patient and family engagement. , AIR researchers ...
(Date:6/25/2016)... ... June 25, 2016 , ... The temporary closing of Bruton Memorial Library on June ... , brings up a new, often overlooked aspect of head lice: the parasite’s ability to ... is not a common occurrence, but a necessary one in the event that lice have ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency Room , the ... Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. , “We ... new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director of First Choice ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson has ... he has implemented orthobiologic procedures as a method for treating his patients. The ... first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016 The Academy ... of recommendations that would allow biopharmaceutical companies ... with entities that make formulary and coverage decisions, a ... "value" of new medicines. The recommendations address ... not appear on the drug label, a prohibition that ...
(Date:6/24/2016)... and SAN CLEMENTE, Calif. , June ... -based mobile pulmonary function testing company, is now able to ... devices developed by ndd Medical Technologies , Inc. ... done in hospital-based labs.  Thanks to ndd,s EasyOne PRO ® , ... , can get any needed testing done in the comfort of ...
(Date:6/24/2016)... -- According to a new market research ... Safety Pen Needles), Needle Length (4mm, 5mm, 6mm, 8mm, ... Purchase (Retail, Non-Retail) - Trends & Global Forecasts to ... for the forecast period of 2016 to 2021. This ... 2021 from USD 1.65 Billion in 2016, growing at ...
Breaking Medicine Technology:
Cached News: